Desheng Lu

Desheng Lu

Auto-generated profile, based on publicly available information

Desheng Lu

University of California at San Diego Moores Cancer Center, La Jolla, CA 92093-0820, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
DLDesheng Lu
Desheng Lu
MCMichael Y. Choi
Michael Y. Choi
JYJian Yu
Jian Yu
JCJanuario E. Castro
Januario E. Castro
TKThomas J. Kipps
Thomas J. Kipps
DCDennis A. Carson
Dennis A. Carson
Salinomycin, an antibiotic potassium ionophore, has been reported recently to act as a selective breast cancer stem cell inhibitor, but the biochemical basis for its anticancer effects is not clear. The Wnt/β-catenin signal transduction pathway plays a central role in stem cell development, and its aberrant activation can cause cancer. In this study, we identified salinomycin as a potent inhibitor of the Wnt signaling cascade. In Wnt-transfected HEK293 cells, salinomycin blocked the phosphorylation of the Wnt coreceptor lipoprotein receptor related protein 6 (LRP6) and induced its degradation. Nigericin, another potassium ionophore with activity against cancer stem cells, exerted similar effects. In otherwise unmanipulated chronic lymphocytic leukemia cells with constitutive Wnt activation nanomolar concentrations of salinomycin down-regulated the expression of Wnt target genes such as LEF1 , cyclin D1 , and fibronectin , depressed LRP6 levels, and limited cell survival. Normal human peripheral blood lymphocytes resisted salinomycin toxicity. These results indicate that ionic changes induced by salinomycin and related drugs inhibit proximal Wnt signaling by interfering with LPR6 phosphorylation, and thus impair the survival of cells that depend on Wnt signaling at the plasma membrane.

14 December 2009 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DLDesheng Lu
Desheng Lu
JLJerry X. Liu
Jerry X. Liu
TETomoyuki Endo
Tomoyuki Endo
HZHaowen Zhou
Haowen Zhou
SYShiyin Yao
Shiyin Yao
DCDennis A. Carson
Dennis A. Carson
Aberrant activation of Wnt/β-catenin signaling promotes the development of several cancers. It has been demonstrated that the Wnt signaling pathway is activated in chronic lymphocytic leukemia (CLL) cells, and that uncontrolled Wnt/β-catenin signaling may contribute to the defect in apoptosis that characterizes this malignancy. Thus, the Wnt signaling pathway is an attractive candidate for developing targeted therapies for CLL. The diuretic agent ethacrynic acid (EA) was identified as a Wnt inhibitor using a cell-based Wnt reporter assay. In vitro assays further confirmed the inhibitory effect of EA on Wnt/β-catenin signaling. Cell viability assays showed that EA selectively induced cell death in primary CLL cells. Exposure of CLL cells to EA decreased the expression of Wnt/β-catenin target genes, including LEF-1, cyclin D1 and fibronectin. Immune co-precipitation experiments demonstrated that EA could directly bind to LEF-1 protein and destabilize the LEF-1/β-catenin complex. N-acetyl-L-cysteine (NAC), which can react with the α, β-unsaturated ketone in EA, but not other anti-oxidants, prevented the drug's inhibition of Wnt/β-catenin activation and its ability to induce apoptosis in CLL cells. Our studies indicate that EA selectively suppresses CLL survival due to inhibition of Wnt/β-catenin signaling. Antagonizing Wnt signaling in CLL with EA or related drugs may represent an effective treatment of this disease.

1 June 2010 in European Journal of Pharmacology
Verified
Journal Article
Closed access
DLDesheng Lu
Desheng Lu
DCDennis A. Carson
Dennis A. Carson

13 December 2005 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
DLDesheng Lu
Desheng Lu
HCHoward B. Cottam
Howard B. Cottam
MCMaripat Corr
Maripat Corr
DCDennis A. Carson
Dennis A. Carson
Activation of the Wnt/β-catenin pathway promotes the development of several cancers and is an attractive target for chemopreventive and chemotherapeutic agents. Nonsteroidal antiinflammatory drugs (NSAIDs) have been reported to antagonize β-catenin function, but their mechanism of action is not known. We demonstrate here that interference with β-catenin function by NSAIDs does not correlate with cyclooxygenase (COX) inhibition. Instead, NSAID inhibition of β-catenin requires the high level expression of peroxisome proliferator-activated receptor γ (PPAR-γ) and its co-receptor retinoid-X-receptor α (RXR-α). Immunoprecipitation experiments show that β-catenin interacts with RXR-α and PPAR-γ in some malignant cells. Repression of β-catenin-dependent transcription by NSAIDs is thus indirect and depends on the coexpression of other nuclear receptors.

30 November 2009 in BMC Pharmacology
Verified
Journal Article
Open access
PDF file
DLDesheng Lu
Desheng Lu
DCDennis A. Carson
Dennis A. Carson
Wnt signaling affects fundamental development pathways by regulating cell proliferation and differentiation. Aberrant activation of Wnt/β-catenin signaling promotes the development of several cancers and is an attractive target for chemopreventive and chemotherapeutic agents.

21 August 2011 in Oncotarget
Verified
Journal Article
Open access
PDF file
DLDesheng Lu
Desheng Lu
DCDennis A. Carson
Dennis A. Carson
Inhibition of Wnt signaling and cancer stem cells